Ivermectin research at the Monash/Doherty institute, Australia

[sprintcyclist]

................. Antiviral Research
Volume 178, June 2020, 104787...............


The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro ............

.......... Highlights
•
Ivermectin is an inhibitor of the COVID-19 causative virus (SARS-CoV-2) in vitro.

•
A single treatment able to effect ~5000-fold reduction in virus at 48 h in cell culture.

•
Ivermectin is FDA-approved for parasitic infections, and therefore has a potential for repurposing.

•
Ivermectin is widely available, due to its inclusion on the WHO model list of essential medicines. ..............

https://www.sciencedirect.com/science/a ... 4220302011

[sprintcyclist]

17 August 2021

Monash University research into Ivermectin as a potential treatment for COVID-19 is being undertaken by Dr Kylie Wagstaff from the Monash Biomedicine Discovery Institute.

Since her team's initial publication showing that Ivermectin could prevent SARS-CoV-2 infection in cells in the laboratory, funding has been secured to undertake additional preclinical tests to better understand the dosing regimen most effective under laboratory conditions.

The findings from this work are now being prepared for submission to a peer-reviewed scientific journal. Monash University is not in a position to communicate on the outcome of this work until it has been subject to rigorous peer review. The pre-clinical laboratory-based findings will be communicated when the research is peer-reviewed and accepted for publication.

Alongside this work, Dr Wagstaff has been working to establish a blinded and randomised clinical trial. The low numbers of COVID cases in Australia in 2020 meant the planned trial in Australia had to be paused. The establishment of a trial depends on Australian and overseas circumstances, and will be communicated when we are in a position to do so.

Dr Wagstaff remains committed to undertaking a trial that will provide a definitive answer to whether or not Ivermectin is a potential treatment for COVID-19.

We note as per the advice issued from the National COVID-19 clinical evidence taskforce, Ivermectin is not to be used for the treatment of COVID-19 outside clinical trials with appropriate ethical approval.

We thank you for your ongoing interest in this work.

https://www.monash.edu/discovery-instit ... n-research